Tyra Biosciences, Inc.

Biotechnology • Healthcare • Carlsbad, CA, United States • TYRA (NMS)

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Tyra Biosciences (NASDAQ:TYRA) Rating Increased to Hold at Wall Street Zen - MarketBeat

MarketBeat • Jan 4

Tyra Biosciences stock hits 52-week high at $26.36 By Investing.com - Investing.com Nigeria

Investing.com Nigeria • Dec 31

(TYRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Stock Traders Daily • Jan 3

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights - PR Newswire

PR Newswire • Nov 5

Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $37 - 富途牛牛

富途牛牛 • Dec 29

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Tyra Biosciences, Inc. had layoffs?

No layoff events have been recorded for Tyra Biosciences, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Tyra Biosciences, Inc. have?

Tyra Biosciences, Inc. has approximately 60 employees.

What industry is Tyra Biosciences, Inc. in?

Tyra Biosciences, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Tyra Biosciences, Inc. a publicly traded company?

Yes, Tyra Biosciences, Inc. is publicly traded under the ticker symbol TYRA on the NMS. The company has a market capitalization of approximately $1.39 billion.

Where is Tyra Biosciences, Inc. headquartered?

Tyra Biosciences, Inc. is headquartered in Carlsbad, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.